A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA

Ashina M. Migraine. N Engl J Med. 2020;383:1866–76. https://doi.org/10.1056/NEJMra1915327.

Article  CAS  PubMed  Google Scholar 

Ray JC, Hutton EJ, Matharu M. OnabotulinumtoxinA in migraine: a review of the literature and factors associated with efficacy. J Clin Med. 2021;10(13):2898.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–18.

Article  PubMed  Google Scholar 

Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.

Article  CAS  PubMed  Google Scholar 

Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.

Article  CAS  PubMed  Google Scholar 

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.

Article  PubMed  Google Scholar 

Kollewe K, Gaul C, Gendolla A, Sommer K. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. J Headache Pain. 2021;22(1):50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, et al. OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience. Neurol Sci. 2018;39(Suppl 1):171–2.

Article  PubMed  Google Scholar 

Santoro A, Copetti M, Miscio AM, Leone MA, Fontana A. Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurol Sci. 2020;41(7):1809–20.

Article  PubMed  PubMed Central  Google Scholar 

Alpuente A, Gallardo VJ, Torres-Ferrús M, Álvarez-Sabin J, Pozo-Rosich P. Short and mid-term predictors of response to onabotulinumtoxinA: real-life experience observational study. Headache. 2020;60(4):677–85.

Article  PubMed  Google Scholar 

Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, et al. Long-term treatment of chronic migraine with onabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna). 2016;123(5):533–40.

Article  CAS  PubMed  Google Scholar 

Beckmann Y, Çetin Üncü F, Kurt İncesu T, Türe S. Effectiveness, safety, and health-related quality of life of chronic migraine patients treated with onabotulinum toxin A. Eur Neurol. 2020;83(5):517–22.

Article  CAS  PubMed  Google Scholar 

Ornello R, Guerzoni S, Baraldi C, Evangelista L, Frattale I, Marini C, et al. Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. J Headache Pain. 2020;21(1):40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aicua-Rapun I, Martínez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, et al. Real-life data in 115 chronic migraine patients treated with onabotulinumtoxin A during more than one year. J Headache Pain. 2016;17(1):112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014;15(1):54.

Article  PubMed  PubMed Central  Google Scholar 

Andreou AP, Trimboli M, Al-Kaisy A, Murphy M, Palmisani S, Fenech C, et al. Prospective real-world analysis of onabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol. 2018;25(8):1069-e83.

Article  CAS  PubMed  Google Scholar 

Wang YF. OnabotulinumtoxinA injection in the treatment of chronic migraine. Prog Brain Res. 2020;255:171–206.

Article  PubMed  Google Scholar 

Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92.

Article  PubMed  PubMed Central  Google Scholar 

Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, et al. European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76.

Article  PubMed  PubMed Central  Google Scholar 

Alpuente A, Gallardo VJ, Torres-Ferrús M, Santos-Lasaosa S, Guerrero AL, Laínez JM, et al. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study. Eur J Neurol. 2020;27(10):2102–8.

Article  CAS  PubMed  Google Scholar 

Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809–26.

Article  PubMed  PubMed Central  Google Scholar 

Guerzoni S, Baraldi C, Pani L. The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine. Neurol Sci. 2022;43(9):5687–95.

Article  PubMed  Google Scholar 

Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2021;35(1):1–6.

Article  CAS  PubMed  Google Scholar 

Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021;22(8):1857–63.

Article  PubMed  Google Scholar 

Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2021;12: 788159.

Article  PubMed  Google Scholar 

Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Additive interaction between onabotulinumtoxin-A and erenumab in patients with refractory migraine. Front Neurol. 2021;12:656294.

Article  PubMed  PubMed Central  Google Scholar 

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37.

PubMed  Google Scholar 

No authors listed. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91.

Article  PubMed  PubMed Central  Google Scholar 

Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129(1):61–70.

Article  CAS  PubMed  Google Scholar 

Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A. Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxin-A treatment. Front Neurol. 2019;10:678.

Article  PubMed  PubMed Central  Google Scholar 

Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470–85.

Article  PubMed  Google Scholar 

D’Amico D. Controversies in migraine: monotherapy. Neurol Sci. 2012;33(Suppl 1):S141-5.

Article  PubMed  Google Scholar 

D’Amico D, Curone M, Tullo V, Proietti Cecchini A, Mea E, Bussone G. Polytherapy for the prophylaxis of chronic migraine: an Italian survey. Neurol Sci. 2011;32(Suppl 1):S185-8.

Article  PubMed  Google Scholar 

Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B, et al. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain. 2022;23(1):38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.

Article  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif